Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Raw Materials (2016 - 2018)

Apyx Medical filings provide 3 years of Raw Materials readings, the most recent being $4.5 million for Q4 2018.

  • On a quarterly basis, Raw Materials fell 12.43% to $4.5 million in Q4 2018 year-over-year; TTM through Dec 2018 was $4.5 million, a 12.43% decrease, with the full-year FY2018 number at $4.5 million, down 12.43% from a year prior.
  • Raw Materials hit $4.5 million in Q4 2018 for Apyx Medical, down from $5.2 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $5.2 million in Q4 2017 to a low of $4.5 million in Q4 2016.
  • Median Raw Materials over the past 3 years was $4.5 million (2016), compared with a mean of $4.7 million.
  • Biggest five-year swings in Raw Materials: grew 14.2% in 2017 and later dropped 12.43% in 2018.
  • Apyx Medical's Raw Materials stood at $4.5 million in 2016, then increased by 14.2% to $5.2 million in 2017, then decreased by 12.43% to $4.5 million in 2018.
  • The last three reported values for Raw Materials were $4.5 million (Q4 2018), $5.2 million (Q4 2017), and $4.5 million (Q4 2016) per Business Quant data.